

## AMENDMENTS TO THE CLAIMS

This listing of the claims will replace, without prejudice, all prior versions, and listings, of the claims in the application.

1. – 13. (Cancelled)

14. (Currently Amended) A pharmaceutical composition comprising a soft tissue targeting complex of thorium-227 and a complexing agent, together with at least one pharmaceutical carrier or excipient wherein the thorium-227 is conjugated to a targeting moiety with bioaffinity, excluding bone-seekers, liposomes, and folate conjugated antibodies or antibody fragments, is chelated by a bifunctional chelator and is not attached to a phosphate group or a bone targeting group, and wherein the thorium-227 is present at a therapeutically effective quantity of at least 25 kBq/kg.

15. (Currently Amended) A soft tissue targeting complex of thorium-227 and a complexing agent wherein the thorium-227 is chelated by a bifunctional chelator, is not attached to a phosphate group or a bone targeting group, and is conjugated to a targeting moiety with bioaffinity, excluding bone-seekers, liposomes, and folate conjugated antibodies or antibody fragments.

16. (Original) A complex as claimed in claim 15 wherein thorium-227 is chelated by a derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.

17. (Original) A method for forming a complex as claimed in claim 16 comprising heating said thorium-227 with said derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid to form a chelated thorium-227 and subsequently attaching said chelated thorium-227 to a targeting moiety.

18. (Cancelled)

19. (Cancelled)